

BIOGRAPHICAL SKETCH

Provide the following information for the key personnel in the order listed for Form Page 2.
Follow this format for each person. DO NOT EXCEED FOUR PAGES.

NAME Paul Blumenthal, M.D., M.P.H.		POSITION TITLE Professor	
EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)			
INSTITUTION AND LOCATION	DEGREE (if applicable)	YEAR(s)	FIELD OF STUDY
Tel Aviv University, Israel		1969-1970	History
University of Illinois	BA	1970-1972	History
The Chicago Medical School, Chicago, IL	MD	1974-1977	Medicine
University of California, Los Angeles, Los Angeles, CA	MPH	1982-1984	Epidemiology

- A.** Positions and Honors. List in chronological order previous positions, concluding with your present position. List any honors. Include present membership on any Federal Government public advisory committee.

1978-1982 Obstetrics & Gynecology Residency, Michael Reese Hospital & Medical Center, Chicago, IL
 1984-1988 Medical Director, Family Planning Program, Michael Reese Hospital, Chicago, IL
 1984-1988 Assistant Professor of Obstetrics & Gynecology, University of Chicago, Chicago, IL
 1987-1988 Medical Director, Planned Parenthood, Chicago, IL Area
 1988-1990 Visiting Lecturer, University of Nairobi, Nairobi, Kenya
 1990- Director, Contraceptive Research & Programs-Dept. of OB/GYN, Johns Hopkins University, Baltimore, MD
 1994-2001 Medical Director, Planned Parenthood of Maryland
 1995-2005 Associate Professor in Obstetrics & Gynecology, Johns Hopkins University, Baltimore, MD
 2005-2007 Professor of Obstetrics and Gynecology, Johns Hopkins University, Baltimore, MD
 2005-2007 Visiting Professor, University of Antananarivo, Antananarivo, Madagascar
 2007- Professor of Obstetrics and Gynecology, Stanford University, Stanford CA

- B.** Selected peer-reviewed publications (in chronological order)

1. Blumenthal P, Jacobson J, Gaffikin L. Problem visits to a family planning clinic. *J Reprod Med* 1988; 33(1):58-62.
2. Blumenthal P, Rosenzweig B. The prophylactic effect of doxycycline on postoperative infection rate after first-trimester abortion (letter). *Obstet Gynecol* 1988;72(1):146.
3. Blumenthal P. Prospective comparison of Dilapan and laminaria for pretreatment of the cervix in second-trimester induction abortion. *Obstet Gynecol* 1988;72(2):243-6.
4. Blumenthal P, Ramanauskas R. Prospective randomized trial of Dilapan versus laminaria for the cervical ripening prior to induction of labor. *Obstet Gynecol* 1990;75(3):365.
5. Blumenthal P. Abortion: Epidemiology, safety, and technique. *Curr Opin Obstet Gynecol* 1992;4(4):506-12.
6. Cullins V, Remsburg R, Blumenthal P, Huggins G. Comparison of adolescent and adult experiences with Norplant levonorgestrel contraceptive implants. *Obstet Gynecol* 1994;83(6):1026-32.
7. Blumenthal P, Remsburg R. A time and cost analysis of the management of incomplete abortion with manual vacuum aspiration. *Int J Gynaecol Obstet* 1994;45(3):261-7.
8. Cullins V, Remsburg R, Blumenthal P, Huggins G. Contraceptive outcomes among post-partum and post-abortal adolescents. *Contraception* 1994;50(5):451-60.

9. Higgins M, Givogre J, Marco A, Blumenthal P, Furman W. Recovery from outpatient laparoscopic tubal ligation is not improved by preoperative administration of ketorolac or ibuprofen. *Anesth Analg* 1994;79(2):274-80.
10. Mauck C, Glover L, Miller E, Allen S, Archer D, Blumenthal P, Rosenzweig A, Dominik R, Sturgen K, Cooper J, Fingerhut F, Peacock L, Gabelnick H. Lea's Shield: a study of the safety and efficacy of a new vaginal barrier contraceptive used with and without spermicide. *Contraception* 1996;53(6):329-35.
11. Blumenthal P, Gaffikin L, Affandi B, Bongiovanni A, McGrath J, Glew G. Training for Norplant implant removal: assessment of learning curves and competency. *Obstet Gynecol* 1997;89(2):174-8.
12. Dunson T, Blumenthal P, Alvarez F, Brache V, Cochon L, Dalberth B, Glover L, Remsburg R, Vu K, Katz D. Timing of onset of contraceptive effectiveness in Norplant implant users. Part I. Changes in cervical mucus. *Fertil Steril* 1998;69(2):258-66.
13. Lammers P, Blumenthal P, Huggins G. Developments in contraception: A comprehensive review of Desogen (desogestrel and ethinyl estradiol). *Contraception* 1998;57(5 Suppl):1S-27S.
14. Gaffikin L, Phiri A, McGrath J, Zinanga A, Blumenthal P. Provider attitudes toward IUD provision in Zimbabwe: Perception of HIV risk and training implications. *Adv Contracept* 1998;14(1):27-39.
15. Mauck C, Callahan M, Weiner D, Dominik R, FemCap Investigators' Group. A comparative study of the safety and efficacy of FemCap, a new vaginal barrier contraceptive, and the Ortho All-Flex diaphragm. *Contraception* 1999;60(2):71-80.
16. Brache V, Blumenthal P, Alvarez F, Dunson T, Cochon L, Faundes A. Timing of onset of contraceptive effectiveness in Norplant implant users. Part II. Effect on the ovarian function in the first cycle of use. *Contraception* 1999;59(4):245-51.
17. Boonstra H, Duran V, Northington Gamble V, Blumenthal P, Dominguez L, Pies C. The "boom and bust phenomenon": The hopes, dreams, and broken promises of the contraceptive revolution. *Contraception* 2000;61(1):9-25.
18. Womack S, Chirenje Z, Blumenthal P, Gaffikin L, McGrath J, Chipato T, Ngwalle E, Shah K. Evaluation of a human papillomavirus assay in cervical screening in Zimbabwe. *BJOG* 2000;107(1):33-8.
19. Womack S, Chirenje Z, Gaffikin L, Blumenthal P, McGrath J, Chipato T, Ngwalle S, Munjoma M, Shah K. HPV-based cervical cancer screening in a population at high risk for HIV infection. *Int J Cancer* 2000;85(2):206-10.
20. Blumenthal P, Gaffikin L, Chirenje Z, McGrath J, Womack S, Shah K. Adjunctive testing for cervical cancer in low resource settings with visual inspection, HPV, and the Pap smear. *Int J Gynaecol Obstet* 2001;72(1):47-53.
21. Mandelblatt, J, Lawrence W, Gaffikin L, Lumbiganon P, and Blumenthal PD. Cost effectiveness of visual inspection with immediate cryotherapy: Results of a Markovian model analysis. *J Natl Cancer Inst.* 2002 Oct 2;94(19):1469-83.
22. Gaffikin L, Blumenthal PD, Emerson M, Limpaphayom K; Royal Thai College of Obstetricians and Gynaecologists (RTCOC)/JHPIEGO Corporation Cervical Cancer Prevention Group. Safety, acceptability, and feasibility of a single-visit approach to cervical-cancer prevention in rural Thailand: a demonstration project. *Lancet* 2003;361(9360):814-20.
23. Jamshidi RM and Blumenthal PD. Digital Assessment of the Reproductive Tract (DART). *JAIDS* 2004 October; 37 (Supplement 3); s171-173.
24. Philip NM, Winikoff B, Moore K, Blumenthal P. A consensus regimen for early abortion with misoprostol. *Int J Gynaecol Obstet.* 2004 Dec;87(3):281-3.
25. Blumenthal PD, Lauterbach M, Sellors J, Denny LA, and Sankaranarayanan R. Training for Cervical Cancer Prevention on Low Resource Settings: Focus on VIA and Cryotherapy. *Int Jnl Gynecol Obstet* 2005 May;89 Suppl 2:S30-7
26. Shannon CS, Winikoff B, Hausknecht R, Schaff E, Blumenthal P, Oyer D, Sankey H, Wolff J, Goldberg R. Multi-center trial of a simplified mifepristone medical abortion regimen. *Obstet Gynecol.* 2005 Feb;105(2):345-51.3

27. Blumenthal PD and Gaffikin L. Cervical Cancer Prevention: Making Programs more Appropriate and Pragmatic. JAMA 2005 November 2; 294 (17) 1-3.
28. Cremer M, Jamshidi RM, Mudersprach L, Tsao-Wei D, Felix JC, and Blumenthal PD. Digital camera assessment for detection of cervical intraepithelial neoplasia in rural El Salvador. Int J Gynecol Obstet, 2005 July 22.
29. Goldie SJ, Gaffikin L, Goldhaber-Fiebert J, Gordillo-Tobar A, Levin C, Mahé C, Wright TC, for the Alliance for Cervical Cancer Prevention Cost Working Group (..Blumenthal PD et al...). Cost-Effectiveness of Cervical-Cancer Screening in Five Developing Countries. NEJM 2005 353;20: 2150-2168.
30. Depineres T, Blumenthal PD, Diener-West M. Postpartum contraception: the New Mexico Pregnancy Risk Assessment Monitoring System. Contraception. 2005 Dec;72(6):422-5.
31. Blumenthal PD, Trussell J, Singh RH, Guo A, Borenstein J, Dubois R, Liu Z. Cost-Effectiveness of Treatments for Dysfunctional Uterine Bleeding in Women Who Need Contraception. Contraception. 2006 Sep;74(3):249-58.
32. Castleman LD, Oanh KTH, Hyman AG, Thuy LT, Blumenthal PD. Introduction of the dilatation and evacuation procedure for second trimester abortion in Vietnam using manual vacuum aspiration and buccal misoprostol. Contraception. 2006 Sep;74(3):272-6.
33. Blumenthal PD. Letter from Madagascar. Obstet Gynecol. 2006 Sep;108:684-6.
34. Liu, Z, Doan Q, Blumenthal P, Dubois R. A systematic review evaluating health-related quality of life, work impairment, and health care costs and utilization in abnormal uterine bleeding. Value in Health 2007 May-Jun;10(3):183-9.
35. Blumenthal PD, Gaffikin L, Deganus S, Lewis R, Emerson M, Adadevoh S et al. Cervical Cancer Prevention: Safety, Acceptability, and Feasibility of a Single-visit Approach in Accra, Ghana. Amer Jnl Obstet Gynecol 2007;196;407.e1-407.e9.
36. Diop A, Raghavan S, Rakotovo JP, Comendant R, Blumenthal PD, Winikoff B. Two routes of administration for misoprostol in the treatment of incomplete abortion: a randomized clinical trial. Contraception. 2009 Jun;79(6):456-62.
37. Trope, L., Blumenthal, P., Chumworathayi, B. "Preventing Cervical Cancer: Stakeholder Attitudes Toward FastHPV- Focused Screening Programs In Roi-Et Province, Thailand". International Journal of Gynecologic Cancer (in press, 2009)

C. Research Support

Ongoing Research Support

Project	PI: Blumenthal	5/2008-present
Gynuity Health Projects		
Evaluation of a Semi-quantitative urine pregnancy test for use in reproductive health settings: Phase 1. Correlation of urine and serum hCG results.		

Project	PI: Blumenthal	5/2008-present
Gynuity Health Projects/FDA		
RCT of misoprostol for management of Intrauterine Fetal Death.		

Completed Research Support

Role: Site Principal Investigator

Project #PP5457/91	PI: Blumenthal and Gaffikin	7/1994-7/1999
JHPIEGO/USAID		

Visual Inspection of the Cervix: Effectiveness in Detection / Prevention of Cervical Cancer Prevention

A prospective cross-sectional study designed to establish the test parameters of visual inspection for the cervix as an alternative to cytology for purposed of cervical cancer screening.

Role: Co-Principal investigator

Project#RPT-001

PI: Cone

10/1997-4/1998

ReProtect, LLC

A Prototype Comparison Study of The Contraceptive-Cup with Buffer-Gel TM

A prospective descriptive study designed to explore the relative acceptability of a diaphragm like device loaded with a microbicide.

Role: Site Principal Investigator

Project#205-US

PI: Winikoff

4/2001-2004

Population Council

Mifepristone and Misoprostol for Early Abortion: Changing the U.S. Regimen

A prospective study designed to establish the safety and efficacy of 200mg of Mifetpristone followed by 400 mcg of oral misoprostol taken at home for termination of pregnancy at < 49 days gestation.

Role: Site Principal Investigator

Project#PSE-301

PI: Blumenthal

8/2002-2005

Barr Laboratories

A Phase III, Randomized, Multicenter, Clinical Trial to Evaluate the Efficacy and Safety of Combination Oral Contraceptive Regimens Utilizing Ethinyl Estradiol During the Pill-Free Interval fir Prevention of Pregnancy in Women

A year long study investigating the efficacy and safety of an oral contraceptive pill that has a 91-day cycle.

Role: Site Principal Investigator

(no project number)

PI: Blumenthal

12/2002-2005

Cervical Cancer Prevention Program (JHPIEGO/ Gates)

Depth of Freeze with Cryotherapy in Relation to Refrigerant, Provider and Technique

A prospective randomized study designed to asses the actual depth of cryonecrosis of the cervix after cryotherapy and observe any differences due to different techniques, provider type (nurse vs doctor) or refrigerant.

Role: PI

Grant#PO1AI45967

PI: Cone R

9/1999-2004

NIH, NIAID, SBIR

Vaginal Residence Time of Human Antibodies

To assess the potential value of using antibodies to coat the vaginal vault for purposes of STD prevention.

Role: Co-investigator

(no Project Number)

PI: Blumenthal

9/2007-6/2008

Stanford University

Stakeholder Attitudes Toward FastHPV- Focused Screening Programs In Roi-Et Province, Thailand

A survey of provider, opinion-leader and policy maker attitudes toward a new, rapid test for HPV in rural Thailand.